PMID- 37235498
OWN - NLM
STAT- MEDLINE
DCOM- 20230815
LR  - 20230815
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 29
IP  - 6
DP  - 2023 Sep
TI  - A Phase III Clinical Trial Evaluating the Efficacy of Yinghua Tablet in the 
      Treatment of Sequelae of Pelvic Inflammatory Disease.
PG  - 170-175
LID - AT8231 [pii]
AB  - OBJECTIVE: To evaluate the efficacy and safety of the Yinghua tablet in treating 
      sequelae of pelvic inflammatory diseases (PID) that manifest as the syndrome of 
      dampness-heat stasis. METHODS: The experimental group enrolled 360 cases, while 
      the control group enrolled 120 cases. The experimental group took Yinghua tablets 
      three times a day, three tablets each time, and the control group took Fuyankang 
      tablets three times a day, three tablets each time. The treatment course was six 
      weeks. Before treatment, at three weeks and six weeks of treatment, the patients 
      were scored for TCM syndrome, clinical symptoms and, signs, and adverse events 
      during treatment were recorded. RESULTS: The experimental group included 340 
      cases, and the control group finally included 114 cases. After six weeks of 
      treatment, statistically significant differences were observed between the two 
      groups in the treatment effect, recovery rate, markedly effective rate, and total 
      effective rate (P < .05). The two groups had no significant difference in the 
      effective rate of local signs (P > .05). However, the two groups had a 
      significant difference in the total effective rate (P < .05). Before and after 
      treatment, traditional Chinese medicine (TCM) symptoms score, symptom sign score, 
      and local sign score were statistically significant (P < .05). The incidence of 
      adverse events (AEs) after taking Yinghua Tablets was 3.61% (13 times), of which 
      the incidence of adverse events related to study drugs was 0.28% (1 case). The 
      AEs of Fuyankang Tablets were 1.67% (2 times), of which the incidence of adverse 
      events related to study drugs was 1.67% (2 cases). There was no significant 
      difference in the incidence of AEs between the two groups as compared to Fisher 
      (P = .3767), indicating that no serious AEs occurred in either group. 
      CONCLUSIONS: Yinghua tablet was effective and safe in treating sequelae of pelvic 
      inflammatory diseases.
FAU - Wang, Shuijing
AU  - Wang S
FAU - Ji, Jing
AU  - Ji J
FAU - Lei, Jiao
AU  - Lei J
FAU - Tian, Sasa
AU  - Tian S
FAU - Yu, Yan
AU  - Yu Y
FAU - Ma, Liangkun
AU  - Ma L
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
RN  - 0 (Tablets)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Pelvic Inflammatory Disease/drug therapy
MH  - Medicine, Chinese Traditional
MH  - Syndrome
MH  - Tablets
EDAT- 2023/05/26 19:14
MHDA- 2023/08/15 06:42
CRDT- 2023/05/26 12:43
PHST- 2023/08/15 06:42 [medline]
PHST- 2023/05/26 19:14 [pubmed]
PHST- 2023/05/26 12:43 [entrez]
AID - AT8231 [pii]
PST - ppublish
SO  - Altern Ther Health Med. 2023 Sep;29(6):170-175.